Home > Neurology > AAN 2022 > Migraine > Intranasal zavegepant safe and well tolerated in healthy adults

Intranasal zavegepant safe and well tolerated in healthy adults

Presented By
Prof. Richard Bertz, University of Pittsburgh, PA, USA
Presented by
Richard Bertz University of Pittsburgh
Conference
AAN 2022
Doi
https://doi.org/10.55788/faa4e7ce
Intranasal zavegepant is in development for the acute treatment of migraine. Escalated to 40 mg/day for up to 14 days, it was safe and well tolerated in healthy adults in 2 sequential phase 1 studies. Doses of ≥10 mg produced exposure that is assumed to be efficacious in adults with migraine. For acute treatment of migraine, non-oral formulations may be useful in a number of situations, including: acute migraine attacks requiring very rapid onset of efficacy; presence of nausea, vomiting, and/or dysphagia; or when oral medications have previously failed. Zavegepant nasal spray is a third-generation, high-affinity, selective, and structurally unique small molecule calcitonin gene-related peptide receptor (CGRP) antagonist. It is the only intranasal CGRP antagonist in late-stage development for the acute treatment of migraine, as Prof. Richard Bertz (University of Pittsburgh, PA, USA) explained. At the AAN 2022 meeting, results were shared of 2 single...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on